The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategy

Triulzi, Darrell J.; Kleinman, Steven; Kakaiya, Ram; Busch, Michael P.; Norris, Philip J.; Steele, Whitney R.; Glynn, Simone A.; Hillyer, Christopher D.; Carey, Patricia M.; Gottschall, Jerome L.; Murphy, Edward L.; Rios, Jorge A.; Ness, Paul M.; Wright, David J.; Carrick, Danielle M.; Schreiber, George B.

doi:10.1111/j.1537-2995.2009.02206.x

Cited by 286 publications

(385 citation statements)

References 22 publications

(42 reference statements)

Supporting

Mentioning

350

Contrasting

Unclassified

Order By: Relevance

“…Firstgeneration immunoassays were susceptible to allo-immunization in pregnancy crossreacting with contaminating cellular proteins from the cells used to culture the HIV virus [14,24,[62][63][64][65]. An association between current pregnancy and false positive HIV tests or between parity and false positive results for newer tests has not been demonstrated.…”

Section: Pregnancymentioning

confidence: 99%

Causes of false-positive HIV rapid diagnostic test results

Klarkowski

O’Brien

Shanks

et al. 2013

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Section: Pregnancymentioning

confidence: 99%

Causes of false-positive HIV rapid diagnostic test results

Klarkowski

O’Brien

Shanks

et al. 2013

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

“…A NBG ratio greater than 10.8 for class I HLA antibodies and 6.9 for class II HLA antibodies was used as the cutoff for a positive result, based on previous work in nonalloexposed populations. 35 …”

Section: Anti-hla Ab Detectionmentioning

confidence: 99%

Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants

Jackman

Deng

Bolgiano

et al. 2013

Blood

Self Cite

View full text Add to dashboard Cite

• High, but not low to moderate, HLA antibody levels are associated with platelet refractoriness.In the Trial to Reduce Alloimmunization to Platelets (TRAP) study, 101 of 530 participants became refractory to platelet transfusions without evidence of HLA or human platelet antigen (HPA) antibodies. We used a more sensitive bead-based assay to detect and quantify HLA antibodies and a qualitative solid-phase enzyme-linked immunosorbet assay for HPA to determine whether low-level antibodies could predict refractoriness in longitudinal panels from 170 lymphocytotoxicity assay (LCA) 2 and 20 LCA Continuing Medical Education online This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. For CME questions, see page 3299. Disclosures The authors, Associate Editor Mortimer Poncz, and CME questions author Charles P. Vega, Associate Professor and Residency Director, Department of Family Medicine, University of California-Irvine, declare no competing financial interests. Learning objectives Upon completion of this activity, participants will be able to:1. Describe alloimmunization due to HLA after platelet transfusion. 2. Analyze the significance of human platelet antigen (HPA) antibodies (Abs) in cases of alloimmunization after transfusion. 3. Evaluate the performance of newer tests for HLA Ab and HPA Ab. 4. Assess the role of HLA Ab and HPA Ab among patients refractory to treatment with platelet transfusions.

show abstract

“…6,7 However, the clinical implications of the presence of HLA antibodies in donors remain unknown. Because HLA antibodies are detected in approximately a quarter of all parous blood donors, 8 SCT from HLA antibody-positive donors are assumed not to be rare events.…”

Section: Introductionmentioning

confidence: 99%